Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAD | Q92934 | 7/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.86 |
| ▸ | MAPT | P10636 | 6/20 | 0.86 |
| ▸ | HPGD | P15428 | 6/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.86 |
| ▸ | MEN1 | O00255 | 4/20 | 0.86 |
| ▸ | LMNA | P02545 | 4/20 | 0.86 |
| ▸ | ACHE | P22303 | 4/20 | 0.86 |
| ▸ | TP53 | P04637 | 3/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.86 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.86 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.86 |
| ▸ | BCHE | P06276 | 3/20 | 0.86 |
| ▸ | RGS17 | Q9UGC6 | 2/20 | 0.86 |
| ▸ | RGS12 | O14924 | 2/20 | 0.86 |
| ▸ | NPC1 | O15118 | 2/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sanguinarium SCHEMBL23524622 | 0.93 | BAD (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL30153784 | 0.93 | BAD (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL30129850 | 0.93 | BAD (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL123241 | 0.93 | BAD (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL29385229 | 0.93 | BAD (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL454298 | 0.92 | ALDH1A1 (0.91) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL8584009 | 0.92 | BAD (0.97) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL43290 | 0.92 | RAC1 (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL30668087 | 0.92 | RAC1 (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL8937106 | 0.92 | BAD (0.97) | BADALDH1A1MAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116687929-A | Application of sanguinarine in preparing medicament for preventing and treating clinical rare fungus related infectious diseases | 山东省妇幼保健院 | 2023-09-05 | — | — | CN | claimed |
| CN-111467347-A | Application of benzophenanthridine alkaloid compound in preparation of calcium-activated chloride channel blocker encoded by ANO1 | 河北医科大学第二医院 | 2020-07-31 | — | — | CN | claimed |
| WO-2011029053-A1 | HUMAN EMBRYONIC STEM CELLS FOR HIGH THROUGHOUT DRUG SCREENING | BUCK INSTITUTE FOR AGE RESEARCH (US) | 2011-03-10 | — | — | WO | claimed |
| US-6004909-A | EXTREME PRESSURE ADDITIVE CONTAINING CHLORHEXIDINE DIGLUCONATE, CETYLPYRIDINIUM CHLORIDE, SANGUINARINE, SODIUM FLUORIDE, THYMOL, BETAINE, AND/OR N,N-DIMETHYL ALKYL AMINE-N-OXIDE | AMERICAN EAGLE TECHNOLOGIES, INC. (US) | 1999-12-21 | — | — | US | claimed |
| US-5869436-A | LUBRICANT FOR TOOLS INTENDED TO CONTACT INTERNAL PARTS OF HUMAN BODY COMPRISING MINERAL OIL, PHOSPHATE ESTER OIL EXTREME PRESSURE ADDITIVE, ANTIOXIDANT/EMULSIFIER, ANTIMICROBIAL COMPOUND | AMERICAN EAGLE TECHNOLOGIES, INC. (US) | 1999-02-09 | — | — | US | claimed |
| EP-0149409-B1 | PLATE DISCLOSING AGENT | VIPONT PHARMACEUTICAL, INC. (US) | 1991-04-10 | — | — | EP | claimed |
| US-4517172-A | SANGUINARINE SALTS, ULTRAVILET LIGHT | VIPONT LABORATORIES, INC. (US) | 1985-05-14 | — | — | US | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4536665-A1 | NOVEL RAS INHIBITORS | KHR Biotec GmbH (DE) | 2025-04-16 | — | — | EP | disclosed |
| CN-118717764-B | Application of chelerythrine and chelidonine combined with sanguinarine in preparation of cancer treatment drugs | 中国人民解放军空军军医大学 | 2025-01-24 | — | — | CN | disclosed |
| US-20240389587-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) | 2024-11-28 | — | — | US | disclosed |
| WO-2024219288-A1 | AGRICULTURAL COMPOSITION AND AGRICULTURAL AQUEOUS DISPERSION | 扶桑化学工業株式会社 | 2024-10-24 | — | — | WO | disclosed |
| CN-118717764-A | Application of chelerythrine and chelidonine combined with sanguinarine in preparation of cancer treatment drugs | 中国人民解放军空军军医大学 | 2024-10-01 | — | — | CN | disclosed |
| US-4737503-A | BENZOPHENANTHRIDINE ALKALOID | VIPONT LABORATORIES, INC. (US) | 1988-04-12 | — | — | US | disclosed |
| US-4735945-A | Method for inhibiting bone resorption and collagenase release | VIPONT LABORATORIES, INC. (US) | 1988-04-05 | — | — | US | disclosed |
| US-4683133-A | PUMPING ALKALOID SALT SOLUTIONS ON GUMS | VIPONT LABORATORIES, INC. (US) | 1987-07-28 | — | — | US | disclosed |
| US-4599228-A | Antimicrobial agent | VIPONT LABORATORIES, INC. (US) | 1986-07-08 | — | — | US | disclosed |
| US-4590061-A | BENZO-C-PHENANTHRIDINE ALKALOIDS | VIPONT LABORATORIES, INC. (US) | 1986-05-20 | — | — | US | disclosed |
| US-4517172-A | SANGUINARINE SALTS, ULTRAVILET LIGHT | VIPONT LABORATORIES, INC. (US) | 1985-05-14 | — | — | US | disclosed |
| US-4406881-A | ANTICARIES AGENTS, ALKALOIDS | VIPONT LABORATORIES (US) | 1983-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | BAD 2878/4885ALDH1A1 568/4885MAPT 696/4885 |
| US-20240389587-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS | XBP1, ERN1, ERN2 | BAD 3051/4885ALDH1A1 4442/4885MAPT 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.